A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

PHASE3CompletedINTERVENTIONAL
Enrollment

391

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

June 30, 2023

Conditions
Anaemia Associated With Chronic Kidney Disease
Interventions
DRUG

efepoetin alfa

The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.

DRUG

Mircera

The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.

Trial Locations (55)

100

Changhua Christian Hospital, Changhua

National Taiwan University Hospital, Taipei

114

Tri-Service General Hospital, Taipei

204

Keelung Chang Gung Memorial Hospital, Keelung

220

Far Eastern Memorial Hospital, Taipei

235

Taipei Medical University - Shuang Ho Hospital, Taipei

433

Kuang Tien General Hospital, Taichung

Chi Mei Medical Center, Tainan City

704

National Cheng Kung University Hospital, Tainan City

813

Kaohsiung Veterans General Hospital, Kaohsiung City

833

Linkou Chang Gung Memorial Hospital, Taoyuan District

970

Hualien Tzu Chi Hospital, Hualien City

1101

National Kidney and Transplant Institute, Quezon

2250

Renal Research Gosford, Gosford

2600

Baguio General Hospital Medical Center, Baguio City

4114

De La Salle Medical and Health Sciences Institute, Dasmariñas

5000

Royal Adelaide Hospital, Adelaide

West Visayas State University Hospital, Iloilo City

6000

Norzel Medical and Diagnostic Clinic, Cebu City

6100

M3 Dialysis Center, Bacolod City

7250

Launceston General Hospital, Launceston

8000

Davao Doctors Hospital, Davao City

10330

Vajira Hospital, Bangkok

10700

Siriraj Hospital, Bangkok

12120

Thammasat University Hospital, Pathum Thani

15200

Hospital Raja Perempuan Zainab II, Kota Bharu

25100

Hospital Tengku Ampuan Afzan, Kuantan

30450

Hospital Raja Permaisuri Bainun, Ipoh

32040

Seri Manjung Hospital, Seri Manjung

34000

Sunpasitthiprasong Hospital, Ubon Ratchathani

40705

Taiching Veterans General Hospital, Taichung

43000

Hospital Kajang, Kajang

Hospital Serdang, Serdang

50200

Maharaj Nakorn Chiang Mai Hospital, Chiang Mai

50586

Hospital Kuala Lumpur, Kuala Lumpur

59100

University of Malaya Medical Centre, Kuala Lumpur

80756

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

83301

Kaohsiung Chang Gung Hospital, Kaohsiung City

90110

Songklanagarind Hospital, Songkhla

96000

Hospital Sibu, Sibu

Unknown

Rspad Gatot Soebroto, Jakarta Pusat

Rumah Sakit Islam Jakarta Cempaka Putih, Jakarta Pusat

Rumah Sakit Islam Jakarta Pondok Kopi, Jakarta Pusat

Rumah Sakit Pgi Cikini, Jakarta Pusat

Rumah Sakit Umum Pusat Fatmawati, Jakarta Pusat

Rumah Sakit Umum Pusat Nasional Dr Cipto Mangunkusumo, Jakarta Pusat

Chungnam National University Hospital, Daejeon

Korea University Ansan Hospital, Gyeonggi-do

Seoul National University Bundang Hospital, Gyeonggi-do

The Catholic University of Korea Incheon St. Mary'S Hospital, Incheon

Chungnam National University Sejong Hospital, Sejong

Kyung Hee University Hospital At Gangdong, Seoul

The Catholic University of Korea Eunpyeong St. Mary'S Hospital, Seoul

The Catholic University of Korea Seoul St. Mary'S Hospital, Seoul

The Catholic University of Korea, Yeouido St. Mary'S Hospital, Seoul

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

PT Kalbe Genexine Biologics

INDUSTRY

NCT04155125 - A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient | Biotech Hunter | Biotech Hunter